NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Belite Bio, Inc (BLTE) Stock Analysis

Belite Bio, Inc (BLTE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BLTE

$153.18

−$1.27 (−0.82%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BLTE with… →

BLTE Key Statistics

As of Oct 21, 2026
Trading
Open
$155.70
Previous Close
$154.45
Day's Range
152.01–156.88
52-Week Range
81.01–200.00
Volume
113.77K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.23
Valuation
Market Cap
$6.15B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
67.53
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.75
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$77.61M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
40.27M
1-Year Return
+66.50%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
183.62K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BLTE closed at $153.18, +66.50% over 1 year.

Belite Bio, Inc (BLTE) has a market capitalization of $6.15B.

In fiscal 2025, BLTE reported revenue of $0.00.

BLTE Stock Return by Calendar Year

Belite Bio, Inc (BLTE) return since Apr 2022: what $10,000 became

1 year
$10,000 $16,650
+66.50%
3 years
$10,000 $44,737
+347.37%
Since Apr 2022
$10,000 $144,646
+1,346.46%

If you had invested $10,000 in Belite Bio, Inc (BLTE) at the close on April 29, 2022, the earliest close on record here, it would have been worth $144,646 at the close on October 21, 2026: +1,346.46% in total, +81.57% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.24%
2025+153.50%
2024+37.92%
2023+51.77%
2022 (partial year)+184.66%

As of October 21, 2026.

BLTE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$77.61M—
2024$0.00−$36.14M—
2023$0.00−$31.63M—
2022$0.00−$12.65M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$84.21M−$77.61M—
2024$0.00—−$40.00M−$36.14M—
2023$0.00—−$31.67M−$31.63M—
2022$0.00—−$12.82M−$12.65M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Belite Bio, Inc (BLTE) carries a market capitalisation of $6.15B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 41.

The 52-week range on file runs from $81.01 to $200.00. The most recent close on file for BLTE is $153.18, dated October 21, 2026. That is −$1.27 (−0.82%) against the previous close. The latest close sits 89.09% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $77.61M. Trailing earnings per share are −2.75.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 67.53.

The reported beta is −1.23. Annualized volatility over the trailing 4 years is 59.07%. Over the trailing twelve months the total return is +66.50%. Across 3 years the annualized return works out at +64.77%.

Growth & Income

The record shows no dividend for BLTE.

2026 is still running; the total return is −4.24% year to date. The strongest complete calendar year on file is 2025 at +153.50%; the weakest is 2024 at +37.92%. Of the 3 complete calendar years on file, 3 finished higher.

Peer Comparison

Belite Bio, Inc (BLTE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Belite Bio, Inc BLTE $6.15B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Belite Bio, Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Visit website →